Top Markets
Coin of the day
Definium Therapeutics, Inc. Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX
Clasificación en acciones #3216
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Precio por acción
$44.42
Última sincronización: 2026-08-25
Capitalización bursátil
$5.90B
Cambio (1 día)
2.66%
Cambio (1 año)
344.66%
País
US
Comercio Definium Therapeutics, Inc. (DFTX)

Categoría

Ratio P/B de Definium Therapeutics, Inc. (DFTX)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Definium Therapeutics, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Definium Therapeutics, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH